A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling

James W. Wisler, Scott M. DeWire, Erin J. Whalen, Jonathan D. Violin, Matthew M Drake, Seungkirl Ahn, Sudha K. Shenoy, Robert J. Lefkowitz

Research output: Contribution to journalArticle

380 Citations (Scopus)

Abstract

For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition. One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. Here, we report that among 16 clinically relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics. We observed that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished by β-arrestin2 siRNA. Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from Gs, is nonetheless able to stimulate β-arrestin-mediated signaling. We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.

Original languageEnglish (US)
Pages (from-to)16657-16662
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number42
DOIs
StatePublished - Oct 16 2007

Fingerprint

Arrestin
Adrenergic Receptors
Adrenergic Antagonists
Heart Failure
Treatment Failure
G-Protein-Coupled Receptor Kinases
HEK293 Cells
Cytoplasmic and Nuclear Receptors
GTP-Binding Proteins
Adenylyl Cyclases
Small Interfering RNA
Phosphotransferases
Myocardial Infarction
Phosphorylation
carvedilol
Ligands
Morbidity
Survival
Mortality
Pharmaceutical Preparations

Keywords

  • β-adrenergic receptor
  • Antagonist
  • ERK 1/2
  • Internalization
  • Scaffold

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

A unique mechanism of β-blocker action : Carvedilol stimulates β-arrestin signaling. / Wisler, James W.; DeWire, Scott M.; Whalen, Erin J.; Violin, Jonathan D.; Drake, Matthew M; Ahn, Seungkirl; Shenoy, Sudha K.; Lefkowitz, Robert J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 42, 16.10.2007, p. 16657-16662.

Research output: Contribution to journalArticle

Wisler, James W. ; DeWire, Scott M. ; Whalen, Erin J. ; Violin, Jonathan D. ; Drake, Matthew M ; Ahn, Seungkirl ; Shenoy, Sudha K. ; Lefkowitz, Robert J. / A unique mechanism of β-blocker action : Carvedilol stimulates β-arrestin signaling. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 42. pp. 16657-16662.
@article{5c4dc15ea9344a188273077c2acf4a45,
title = "A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling",
abstract = "For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition. One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. Here, we report that among 16 clinically relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics. We observed that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished by β-arrestin2 siRNA. Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from Gs, is nonetheless able to stimulate β-arrestin-mediated signaling. We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.",
keywords = "β-adrenergic receptor, Antagonist, ERK 1/2, Internalization, Scaffold",
author = "Wisler, {James W.} and DeWire, {Scott M.} and Whalen, {Erin J.} and Violin, {Jonathan D.} and Drake, {Matthew M} and Seungkirl Ahn and Shenoy, {Sudha K.} and Lefkowitz, {Robert J.}",
year = "2007",
month = "10",
day = "16",
doi = "10.1073/pnas.0707936104",
language = "English (US)",
volume = "104",
pages = "16657--16662",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "42",

}

TY - JOUR

T1 - A unique mechanism of β-blocker action

T2 - Carvedilol stimulates β-arrestin signaling

AU - Wisler, James W.

AU - DeWire, Scott M.

AU - Whalen, Erin J.

AU - Violin, Jonathan D.

AU - Drake, Matthew M

AU - Ahn, Seungkirl

AU - Shenoy, Sudha K.

AU - Lefkowitz, Robert J.

PY - 2007/10/16

Y1 - 2007/10/16

N2 - For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition. One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. Here, we report that among 16 clinically relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics. We observed that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished by β-arrestin2 siRNA. Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from Gs, is nonetheless able to stimulate β-arrestin-mediated signaling. We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.

AB - For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition. One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. Here, we report that among 16 clinically relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics. We observed that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished by β-arrestin2 siRNA. Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from Gs, is nonetheless able to stimulate β-arrestin-mediated signaling. We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.

KW - β-adrenergic receptor

KW - Antagonist

KW - ERK 1/2

KW - Internalization

KW - Scaffold

UR - http://www.scopus.com/inward/record.url?scp=36749094552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749094552&partnerID=8YFLogxK

U2 - 10.1073/pnas.0707936104

DO - 10.1073/pnas.0707936104

M3 - Article

C2 - 17925438

AN - SCOPUS:36749094552

VL - 104

SP - 16657

EP - 16662

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 42

ER -